Home Page News Statistics API Review Formulation Monthly Im&Ex report All Information
     
Keyword:
 E-mail:xuezhe@healthoo.com
 Tel.:86-10-68032463
  Our services:
 China Im\Ex data service
 Service fees of Chinese Vision
 Our service items
Online information introduction
Monthly information
Conference on ...
Information Release...
Internationalization&nbs...
Welcome to Pro...
Healthoo.com Carbap...
APIs Innovation&nbs...
China Import Export Statistics Report In...
API Export Price by ...
Tylosin Bulk Drug Export&...
China Monthly Export Stat...
China Monthly Export Stat...
China Monthly Export Stat...
Your position:www.healthoo.com >> EN >> Formulation
RemeGen ADC drug RC108 combined with PD-1 has been approved for the treatment of solid tumors in phase Ⅰb/Ⅱ clinical trial2023-06-14
Boanbiodulaglutide injection BA5101 completed phase III clinical trial2023-06-08
With annual sales of Times="32".4 billion, the race is on for the first copy of this innovative drug2023-06-08
The legendary Bio-Citagiorencel reduces the risk of disease progression or death by 74%2023-06-08
Antidepressant market usher in new opportunities, see "a brother" status fall to who hand?2023-05-11
Analysis of 70 macrocyclic drugs approved by the FDA2023-05-11
$860 million market size, PDC drug development market analysis2023-05-11
Only 3 drugs have been approved! Frozen life, Times="32".16 million worth of drugs2023-05-11
Enbio: Partnered with BioNTech to advance the development of next-generation antibody conjugated drugs (ADCs)2023-04-20
Cure diabetes obesity with printed materials? Novo Nordisk Introduces Cell Therapy for .6 billion2023-04-20
Multiple product indications withdrawn, FDA accelerated Approval How to reform?2023-04-20
Maxpro: Completed merger with SPAC Maxpro listed on Nasdaq2023-03-31
Meinol completed the B round financing of over 100 million yuan, continued to accelerate the overall layout of CXO industry2023-03-31
Received orphan drug recognition! Shanghai Pharmaceutical SPH4336 breakthrough liposarcoma2023-03-31
Yi Neng Pharmaceutical, A leading TCM CXO enterprise, has completed a series of financing of over 100 million yuan, enabling the modernization innovation research development of TCM2023-03-31
After 20 years of failure, Is there Hope for targeted Aβ therapy for AD?2023-03-20
$161 million! China Biopharmaceutical completes acquisition of F-star Therapeutics2023-03-10
The different paths of Chinese foreign diabetes giants: double males double bears2023-03-03
Sanofis cracked quadrivalent influenza virus vaccine, VaxigripTetra?, was approved for sale in China2023-03-03
Star ADC Therapy DS-8201 approved for market in China!2023-03-03
Star ADC Therapy DS-8201 approved for market in China!2023-03-01
For the first time, heparin was incorporated into the country, which ushered in a change in the ten-billion market2023-03-01
Asia Hong Pharma announced that it has co-developed an innovative tumor therapy based on AI+RNA technology route with ReviR2023-02-16
Dapagliflozin is approved in the EU for the treatment of symptomatic chronic heart failure2023-02-16
Tronsound long-acting IL-36R antibody obtained FDA clinical IND2023-02-16
Hua Quejing Medical has received tens of millions of yuan of exclusive investment from Shenzhen Venture Capital continues to lead the intelligent development of rehabilitation robots2023-02-10
Eli Lilly Tirzepatides Phase III trial in obese or overweight adult patients in China was successful2023-02-10
Is the class solidified? From Biotech to Pharma2023-02-10
Ribo Biologics announced that the worlds first FIH application for a siRNA drug targeting FXI has been successfully approved by HREC in Australia2023-02-10
Asia Hong Pharma announced that it has co-developed an innovative tumor therapy based on AI+RNA technology route with ReviR2023-02-10
Dapagliflozin is approved in the EU for the treatment of symptomatic chronic heart failure2023-02-10
Tronsound long-acting IL-36R antibody obtained FDA clinical IND2023-02-10
1499个 页次:2/4732个/页 首页 上一页 下一页 尾页 转到:
Our Advantages of Reports
①All reports written by ourselves
②All data having original sources
③Information is the latest
④Continuous historical data
⑤Objective analysis and remark
Purchase Flow of Reports
①Confirm purchase (If necessary sign the contract)
②Transfer payment to company's bank account
③After accepting payment we email the report to clients (PDF format)
④Send the invoice
Bank account
①Beneficiary's Name:Beijing orientbit technology ltd
②Beneficiary's Account No.:110060239018002127366
③Name of bank:Bank of Communications Beijing Branch,Fuwai Sub-Branch
④Address of bank:NO7,FUWAISTREET,XICHENG DISTRICT,BEIJING,CHINA SWIFT CODE:COMMCNSHBJG
Address: Suite 13F,NO2 Building, FuXing International, TianHua North Street, Yizhuang, Daxing District, Beijing, P.R. China
Tel:+86-10-68032463